NCT03000634 2024-09-05
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Phase 2 Withdrawn
Clinical Trials
17 trialsNCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04223661 2022-12-08
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Indiana University
Phase 2 Withdrawn
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT04288765 2021-07-09
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Grupo Cooperativo de HemopatÃas Malignas
Phase 3 Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03168100 2019-01-28
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
University of Arkansas
Phase 2 Withdrawn
NCT02986451 2018-08-14
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT02155634 2018-04-10
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
Phase 3 Withdrawn
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03283046 2017-09-20
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03191981 2017-08-24
MUKfourteen
University of Leeds
Phase 1/2 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT01055301 2015-03-06
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Withdrawn